« Return to News | R&D Trends

EGEN, Nanotechnology Characterization Lab collaborate in brain cancer research

Tuesday, September 27, 2011 11:09 AM

EGEN is collaborating with the National Cancer Institute's Nanotechnology Characterization Laboratory in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.

EGEN's candidate gene therapy, which  relies on nanoparticles for effective delivery to the tumor site, is already being evaluated in phase I and II clinical trials in patients with colorectal and ovarian cancers. EGEN is seeking to begin phase I trials against glioblastoma, a brain cancer that is difficult to treat.

The NCI's Nanotechnology Characterization Laboratory, operated under contract by SAIC-Frederick, is part of the NCI Alliance for nanotechnology in cancer, and a partnership between NCI, the National Institute of Standards and Technology, and the FDA. The laboratory evaluates nanoparticles for their physical and chemical properties and for their behavior in laboratory and animal models -- all prerequisite to human testing in medical procedures.

"By working with NCL we are hopeful that we can quickly advance this treatment strategy into additional cancer indications, including brain tumors, where we believe that it may offer significant therapeutic benefit,” said Dr. Jason Fewell, vice president of preclinical research and development for EGEN.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.